X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (68) 68
oncology (53) 53
male (51) 51
female (49) 49
index medicus (45) 45
middle aged (43) 43
aged (41) 41
adult (36) 36
chemotherapy (36) 36
aged, 80 and over (28) 28
treatment outcome (27) 27
lung neoplasms - drug therapy (26) 26
carcinoma, non-small-cell lung - drug therapy (22) 22
cancer (21) 21
lung neoplasms - pathology (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
lung cancer, non-small cell (18) 18
care and treatment (17) 17
antineoplastic agents - therapeutic use (16) 16
lung cancer (15) 15
disease-free survival (14) 14
further section · weitere sektionen (13) 13
hematology, oncology and palliative medicine (13) 13
lung neoplasms - mortality (13) 13
survival (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
disease progression (12) 12
neoplasm staging (12) 12
respiratory system (12) 12
carcinoma, non-small-cell lung - pathology (11) 11
metastasis (11) 11
carcinoma, non-small-cell lung - mortality (10) 10
open-label (10) 10
prognosis (10) 10
italy (9) 9
metastases (9) 9
mutation (9) 9
patients (9) 9
retrospective studies (9) 9
therapy (9) 9
antineoplastic agents - adverse effects (8) 8
cancer therapies (8) 8
protein kinase inhibitors - therapeutic use (8) 8
pulmonary/respiratory (8) 8
survival analysis (8) 8
survival rate (8) 8
trial (8) 8
tumors (8) 8
carcinoma, non-small-cell lung - secondary (7) 7
colorectal cancer (7) 7
crizotinib (7) 7
diagnosis (7) 7
docetaxel (7) 7
erlotinib (7) 7
non-small cell lung cancer (7) 7
nsclc (7) 7
radiotherapy (7) 7
time factors (7) 7
analysis (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
cisplatin (6) 6
clinical trials (6) 6
clinical-trials (6) 6
colorectal neoplasms - drug therapy (6) 6
deoxycytidine - analogs & derivatives (6) 6
drug therapy (6) 6
gefitinib (6) 6
guanine - analogs & derivatives (6) 6
hiv (6) 6
neoplasms (6) 6
pemetrexed (6) 6
adenocarcinoma - drug therapy (5) 5
administration, oral (5) 5
cancer patients (5) 5
carboplatin (5) 5
carcinoma (5) 5
ceritinib (5) 5
cisplatin - administration & dosage (5) 5
deoxycytidine - administration & dosage (5) 5
drug administration schedule (5) 5
haart (5) 5
hiv infections - complications (5) 5
hiv infections - drug therapy (5) 5
kaplan-meier estimate (5) 5
kidney neoplasms - pathology (5) 5
liver neoplasms - secondary (5) 5
lung neoplasms - diagnosis (5) 5
lung neoplasms - genetics (5) 5
medicine (5) 5
mesothelioma (5) 5
prospective studies (5) 5
quinazolines - therapeutic use (5) 5
research (5) 5
risk factors (5) 5
surgery (5) 5
toxicity (5) 5
1st-line treatment (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
carboplatin - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 713 - 721
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
Current Cancer Drug Targets, ISSN 1568-0096, 2018, Volume 18, Issue 5, pp. 405 - 409
Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm,... 
Therapy | Chemotherapy | NSCLC | Prognoses | Cost | Metastases | Target agents | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | CARBOPLATIN | cost | therapy | prognoses | chemotherapy | PACLITAXEL | metastases | INHIBITION | ONCOLOGY | CRIZOTINIB | MUTATIONS | target agents | ERLOTINIB | Lung cancer | Non-small cell lung carcinoma | Cost analysis | Survival | System effectiveness | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 6_suppl, pp. 300 - 300
300 Background: Docetaxel (Doc) and Cabazitaxel (Cab) every 3 weeks with daily prednisone are standard first and second line chemotherapies in mCRPC. In daily... 
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2018, Volume 19, Issue 12, pp. 1654 - 1667
Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of mutations. In a phase 1 study,... 
MULTICENTER | EFFICACY | ONCOLOGY | CERITINIB | CRIZOTINIB | OPEN-LABEL | INHIBITOR | ROS1 | CHEMOTHERAPY | Care and treatment | Research | Lung cancer, Non-small cell | Analysis | Oncology, Experimental | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e16081 - e16081
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2014, Volume 88, Issue 5, pp. 1114 - 1119
Journal Article
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, ISSN 1574-8928, 2019, Volume 14, Issue 3, pp. 242 - 257
Background: Lung cancer is the most frequent cause of cancer-related death. In the last decades, the introduction of targeted therapies and more recently, of... 
toxicity | ALK | targeted therapy | MULTICENTER | patent | OPEN-LABEL | ATEZOLIZUMAB | DOCETAXEL | CHEMOTHERAPY | lung cancer | PEMBROLIZUMAB | PHARMACOKINETICS | ONCOLOGY | Immunotherapy | CRIZOTINIB | side effects | PHARMACOLOGY & PHARMACY | NIVOLUMAB
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 799 - 811
Journal Article